Published in Lancet Neurol on January 10, 2012
Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) (MSCIMS) | NCT00395200
Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med (2013) 2.60
Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol (2012) 2.36
Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. Am J Physiol Cell Physiol (2012) 1.67
Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med (2013) 1.33
MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation. Stem Cells Int (2013) 1.30
Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev (2013) 1.26
Advances in stem cell therapy for spinal cord injury. J Clin Invest (2012) 1.24
Mesenchymal stem cells in tumor development: emerging roles and concepts. Cell Adh Migr (2012) 1.24
Progress of mesenchymal stem cell therapy for neural and retinal diseases. World J Stem Cells (2014) 1.20
Vision and vision-related outcome measures in multiple sclerosis. Brain (2014) 1.08
How stem cells speak with host immune cells in inflammatory brain diseases. Glia (2013) 1.08
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol (2015) 1.05
Mesenchymal stem cell transplantation in multiple sclerosis. J Neurol Sci (2013) 1.04
Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis (2016) 1.03
Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Res Ther (2013) 1.03
CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities. PLoS One (2013) 1.00
Treatment strategies for inherited optic neuropathies: past, present and future. Eye (Lond) (2014) 0.99
Enhancing the efficacy of mesenchymal stem cell therapy. World J Stem Cells (2014) 0.99
Concise review: adult mesenchymal stem cells, adult neural crest stem cells, and therapy of neurological pathologies: a state of play. Stem Cells Transl Med (2013) 0.96
Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model. Stem Cells Transl Med (2013) 0.96
Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Reports (2014) 0.94
Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One (2014) 0.94
Leber hereditary optic neuropathy: current perspectives. Clin Ophthalmol (2015) 0.94
Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol (2013) 0.92
MSCs: science and trials. Nat Med (2013) 0.90
Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis. Int J Mol Sci (2015) 0.90
Serum-starved adipose-derived stromal cells ameliorate crescentic GN by promoting immunoregulatory macrophages. J Am Soc Nephrol (2013) 0.89
The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis. Am J Stem Cells (2013) 0.89
Stem cells in Texas: Cowboy culture. Nature (2013) 0.89
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. Neurotherapeutics (2016) 0.88
The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. Immunotherapy (2012) 0.88
Gene therapy of multiple sclerosis using interferon β-secreting human bone marrow mesenchymal stem cells. Biomed Res Int (2013) 0.87
Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. Stem Cells Transl Med (2012) 0.87
Human mesenchymal stromal cell-mediated immunoregulation: mechanisms of action and clinical applications. Bone Marrow Res (2013) 0.85
Fibrin glue improves the therapeutic effect of MSCs by sustaining survival and paracrine function. Tissue Eng Part A (2013) 0.85
Experimental and therapeutic opportunities for stem cells in multiple sclerosis. Int J Mol Sci (2012) 0.84
Transplantation of autologous adipose stem cells lacks therapeutic efficacy in the experimental autoimmune encephalomyelitis model. PLoS One (2014) 0.84
Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis. Mol Ther (2016) 0.84
Are mesenchymal stromal cells immune cells? Arthritis Res Ther (2015) 0.83
Emerging stem cell therapies: treatment, safety, and biology. Stem Cells Int (2012) 0.83
Mesenchymal stem cell-based therapy in a mouse model of experimental autoimmune encephalomyelitis (EAE). Methods Mol Biol (2014) 0.83
Feasibility of cell therapy in multiple sclerosis: a systematic review of 83 studies. Int J Hematol Oncol Stem Cell Res (2013) 0.83
Perivascular mesenchymal stem cells in the adult human brain: a future target for neuroregeneration? Clin Transl Med (2012) 0.82
Imaging outcomes for trials of remyelination in multiple sclerosis. J Neurol Neurosurg Psychiatry (2014) 0.82
Regenerative cellular therapies for neurologic diseases. Brain Res (2015) 0.82
Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage. Curr Neuropharmacol (2016) 0.81
Optimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cells. Int J Biol Sci (2015) 0.81
Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation. Clin Dev Immunol (2012) 0.81
Inflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMD. Mol Ther (2014) 0.81
Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. PLoS One (2014) 0.80
Intranasal Delivery of Neural Stem Cells: A CNS-specific, Non-invasive Cell-based Therapy for Experimental Autoimmune Encephalomyelitis. J Clin Cell Immunol (2013) 0.80
Mesenchymal stem/stromal cells-a key mediator for regeneration after perinatal morbidity? Mol Cell Pediatr (2016) 0.80
Long-term therapeutic effects of mesenchymal stem cells compared to dexamethasone on recurrent experimental autoimmune uveitis of rats. Invest Ophthalmol Vis Sci (2014) 0.80
The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Prog Neurobiol (2015) 0.79
Loss of galectin-3 decreases the number of immune cells in the subventricular zone and restores proliferation in a viral model of multiple sclerosis. Glia (2015) 0.79
The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies. Adv Biomed Res (2016) 0.78
Effects of a ceramic biomaterial on immune modulatory properties and differentiation potential of human mesenchymal stromal cells of different origin. Tissue Eng Part A (2014) 0.78
Bone Marrow-Derived Cells as a Therapeutic Approach to Optic Nerve Diseases. Stem Cells Int (2015) 0.78
Prospects for therapeutic tolerance in humans. Curr Opin Rheumatol (2014) 0.78
Neurorepair with mesenchymal stem cells: hope or hype? Lancet Neurol (2012) 0.77
Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis. Discov Med (2013) 0.77
Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications. J Neurosci Res (2017) 0.77
Are nestin-positive mesenchymal stromal cells a better source of cells for CNS repair? Neurochem Int (2016) 0.77
Adipose-Derived Mesenchymal Stem Cells Restore Impaired Mucosal Immune Responses in Aged Mice. PLoS One (2016) 0.76
Defining recovery neurobiology of injured spinal cord by synthetic matrix-assisted hMSC implantation. Proc Natl Acad Sci U S A (2017) 0.76
Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration. Stem Cells Transl Med (2015) 0.76
From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases. Biomed Res Int (2013) 0.76
Stem cells: Don't believe the hype. Nature (2012) 0.76
Oligodendrocytes engineered with migratory proteins as effective graft source for cell transplantation in multiple sclerosis. Cell Med (2014) 0.76
Restrained Th17 response and myeloid cell infiltration into the central nervous system by human decidua-derived mesenchymal stem cells during experimental autoimmune encephalomyelitis. Stem Cell Res Ther (2016) 0.76
Multiple Sclerosis and Obesity: Possible Roles of Adipokines. Mediators Inflamm (2016) 0.76
Stem Cell Imaging: Tools to Improve Cell Delivery and Viability. Stem Cells Int (2016) 0.75
Therapeutic effects of human adipose tissue-derived stem cell (hADSC) transplantation on experimental autoimmune encephalomyelitis (EAE) mice. Sci Rep (2017) 0.75
MSC Therapeutics in Chronic Inflammation. Curr Stem Cell Rep (2016) 0.75
Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis. Int J Stem Cells (2016) 0.75
Gender difference in the neuroprotective effect of rat bone marrow mesenchymal cells against hypoxia-induced apoptosis of retinal ganglion cells. Neural Regen Res (2016) 0.75
Mesenchymal stem cells protect against the tissue fibrosis of ketamine-induced cystitis in rat bladder. Sci Rep (2016) 0.75
Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function. Stem Cells Int (2017) 0.75
Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther (2013) 0.75
Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health. Stem Cell Res Ther (2017) 0.75
Mechanical fibrinogen-depletion supports heparin-free mesenchymal stem cell propagation in human platelet lysate. J Transl Med (2015) 0.75
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. Int J Mol Sci (2016) 0.75
Comparative miRNA-Based Fingerprinting Reveals Biological Differences in Human Olfactory Mucosa- and Bone-Marrow-Derived Mesenchymal Stromal Cells. Stem Cell Reports (2016) 0.75
Transdifferentiation of autologous bone marrow cells on a collagen-poly(ε-caprolactone) scaffold for tissue engineering in complete lack of native urothelium. J R Soc Interface (2014) 0.75
Stem cells: Stemming the tide. Nature (2016) 0.75
Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials. World J Stem Cells (2016) 0.75
Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. J Transl Med (2016) 0.75
Mesenchymal Stem Cell Therapy for Inflammatory Skin Diseases: Clinical Potential and Mode of Action. Int J Mol Sci (2017) 0.75
Tai chi for health benefits in patients with multiple sclerosis: A systematic review. PLoS One (2017) 0.75
Stem cells: from animal models to clinical practice. J Neurol (2012) 0.75
Mesenchymal stromal cells enhance the engraftment of hematopoietic stem cells in an autologous mouse transplantation model. Stem Cell Res Ther (2015) 0.75
Stem Cells Therapy in Multiple Sclerosis - A New Hope for Progressive Forms. J Stem Cells Regen Med (2016) 0.75
Valproic acid enforces the priming effect of sphingosine-1 phosphate on human mesenchymal stem cells. Int J Mol Med (2017) 0.75
Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis. Front Neurosci (2017) 0.75
Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler (2017) 0.75
CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells. Exp Neurol (2017) 0.75
Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother (2014) 0.75
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Multiple sclerosis. Lancet (2008) 13.77
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 10.26
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med (2008) 6.86
Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci (2008) 6.16
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood (2005) 5.82
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol (2010) 4.03
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol (2004) 3.23
Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells (2009) 3.01
The epidemiology of multiple sclerosis in Europe. Eur J Neurol (2006) 2.80
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol (2007) 2.64
The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J Cell Physiol (2009) 2.00
Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol (2008) 1.84
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol (2011) 1.73
Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol (2010) 1.69
Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol (2003) 1.55
Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol (2007) 1.39
Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest (2006) 1.35
Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J Neurosci Res (2006) 1.34
Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus (2009) 1.31
Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis. J Neurol (2009) 1.29
Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells. Stem Cells (2006) 1.14
Human mesenchymal stem cells signals regulate neural stem cell fate. Neurochem Res (2006) 1.08
The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis. Curr Stem Cell Res Ther (2011) 1.02
Linear mixed effects models. Methods Mol Biol (2007) 0.86
The curious incident of disability in multiple sclerosis trials. Lancet Neurol (2006) 0.83
Proof of concept studies for tissue-protective agents in multiple sclerosis. Mult Scler (2009) 0.83
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med (2007) 17.06
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol (2011) 6.77
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med (2012) 6.51
Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci (2011) 5.24
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med (2002) 3.74
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 3.68
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol (2005) 3.45
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet (2012) 3.31
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol (2004) 3.23
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet (2006) 3.13
Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. Cereb Cortex (2004) 3.03
MALT lymphoma: from morphology to molecules. Nat Rev Cancer (2004) 2.75
Improving the translational hit of experimental treatments in multiple sclerosis. Mult Scler (2010) 2.73
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med (2005) 2.54
Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol (2007) 2.53
A high-density screen for linkage in multiple sclerosis. Am J Hum Genet (2005) 2.50
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol (2005) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol (2009) 2.43
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood (2012) 2.39
The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A (2009) 2.38
Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage (2006) 2.35
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood (2002) 2.26
Neuroplasticity predicts outcome of optic neuritis independent of tissue damage. Ann Neurol (2010) 2.24
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2008) 2.20
Robust, persistent transgene expression in human embryonic stem cells is achieved with AAVS1-targeted integration. Stem Cells (2007) 2.20
An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain (2007) 2.18
Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A (2012) 2.14
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology (2002) 2.06
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Case reports in The Lancet. Lancet (2003) 2.03
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol (2010) 2.03
Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke (2002) 2.00
Motor system activation after subcortical stroke depends on corticospinal system integrity. Brain (2006) 1.99
A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol (2007) 1.99
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet (2009) 1.97
Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells. Stem Cells (2009) 1.96
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol (2008) 1.91
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest (2009) 1.87
Embryonic stem cell-derived neural progenitors display temporal restriction to neural patterning. Stem Cells (2006) 1.82
Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation. Magn Reson Med (2008) 1.82
Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. Nature (2013) 1.79
Lineage-specific distribution of high levels of genomic 5-hydroxymethylcytosine in mammalian development. Cell Res (2011) 1.76
Investigating cervical spinal cord structure using axial diffusion tensor imaging. Neuroimage (2002) 1.76
Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell (2005) 1.74
Dopamine from the brain promotes spinal motor neuron generation during development and adult regeneration. Dev Cell (2013) 1.74
Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood (2003) 1.73
Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol (2005) 1.72
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain (2010) 1.71
Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain (2004) 1.71
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Effect sizes can be misleading: is it time to change the way we measure change? J Neurol Neurosurg Psychiatry (2010) 1.70
MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood (2003) 1.69
New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol (2003) 1.66
Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology (2009) 1.66
K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J Virol (2002) 1.65
Confounding underlies the apparent month of birth effect in multiple sclerosis. Ann Neurol (2013) 1.62
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
The evolution of prefrontal inputs to the cortico-pontine system: diffusion imaging evidence from Macaque monkeys and humans. Cereb Cortex (2005) 1.61
A highly enriched niche of precursor cells with neuronal and glial potential within the hair follicle dermal papilla of adult skin. Stem Cells (2007) 1.60
Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord (2004) 1.59
Disability, atrophy and cortical reorganization following spinal cord injury. Brain (2011) 1.58